Showing 941-950 of 2538 results for "".
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- FDA Approves Neonatal Fc Receptor Blocker Treatment for Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/fda-approves-neonatal-fc-receptor-blocker-treatment-for-individuals-with-generalized-myasthenia-gravis/2474395/The Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab; Johnson & Johnson, New Brunswick, NJ) for the treatment of individuals aged >12 years with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK)
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar
- Potential Myasthenia Gravis Treatment Receives FDA Priority Reviewhttps://practicalneurology.com/news/potential-myasthenia-gravis-treatment-receives-fda-priority-review/2473769/The Food and Drug Administration (FDA) has granted Priority Review designation to the Biologics License Application (BLA) for nipocalimab (Johnson & Johnson, New Brunswick, NJ) for the treatment of people with generalized myasthenia gravis (gMG) who are antibody positive, including anti-acety
- Over $500,000 Awarded for ALS and Mitochondrial Myopathies Researchhttps://practicalneurology.com/news/over-500000-awarded-for-als-and-mitochondrial-myopathies-research/2470938/The Muscular Dystrophy Association (MDA; Chicago, IL) has partnered with the French Muscular Dystrophy Association (AFM-Téléthon; Evry, France) to award a total of $510,000 in grant funding across 2 research projects. The grant funding is intended to accelerate the development of tr
- Muscular Dystrophy Association Launches Initiative to Support the Development of Treatments for Ultra-Rare Neuromuscular Diseaseshttps://practicalneurology.com/news/muscular-dystrophy-association-launches-initiative-to-support-the-development-of-treatments-for-ultra-rare-neuromuscular-diseases/2470571/The Muscular Dystrophy Association (MDA) announced the launch of the MDA Kickstart Program, an initiative to advance the development of treatments for ultra-rare neuromuscular diseases. The first project under the MDA Kickstart Program will focus on the development of a gene therapy for a rare fo
- Cerenovus Launches Initiatives to Address Racial and Ethnic Disparities in Stroke Carehttps://practicalneurology.com/news/cerenovus-launches-initiatives-to-address-racial-and-ethnic-disparities-in-stroke-care-1/2470518/Cerenovus (Irvine, CA), part of Johnson & Johnson MedTech (Warsaw, IN), recently announced initiatives to reduce racial and ethnic disparities in stroke treatment along the continuum of care. The company has launched an online Digital Health Equity Hub that contains i
- Muscular Dystrophy Association Applauds Landmark Proposal on Accessible Air Travelhttps://practicalneurology.com/news/muscular-dystrophy-association-applauds-landmark-proposal-on-accessible-air-travel/2470417/The Muscular Dystrophy Association (MDA) celebrates a significant milestone in air travel accessibility for individuals with disabilities related to a proposal aimed at enhancing the safety, rights, and dignity of air travelers with disabilities made by the Biden Administration and the US Departm
- Muscular Dystrophy Association Announces the Start of 30 Days of Strength Campaignhttps://practicalneurology.com/news/mda-announces-the-start-of-30-days-of-strength-campaign/2470289/The Muscular Dystrophy Association (MDA) has announced the start of its 30 Days of Strength campaign for September, which is National Muscular Dystrophy Awareness Month. Throughout the month, the MDA will collaborate with influencers and community leaders, including Nyheim Hines, running back for
- FDA Grants Fast Track Designation to Factor XIa Inhibitor Milvexian to Treat Stroke, ACS, and AFhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-factor-xia-inhibitor-milvexian-to-treat-stroke-acs-and-af/2470191/The investigational factor XIa (FXIa) inhibitor milvexian (Janssen Pharmaceuticals, Johnson & Johnson, Beerse, Belgium; Bristol Myers Squibb, New York, NY) was granted Fast Track designation by the Food and Drug Adminis